Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | NRP1 | O14786 | 4/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470824 | 1.00 | CYP1A2 (0.56) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29559662 | 1.00 | CYP1A2 (0.56) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29394951 | 1.00 | CYP1A2 (0.56) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL1735525 | 0.93 | CYP2C19 (0.65) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL27898034 | 0.93 | CYP2C19 (0.65) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29350539 | 0.92 | FOLH1 (0.55) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL1738257 | 0.90 | NPY1R (0.53) | CYP1A2GLATSHRNFKB1APEX1 | |
| Thymotrinan SCHEMBL15532089 | 0.90 | NPY1R (0.53) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29457346 | 0.90 | NPY1R (0.51) | CYP1A2GLATSHRNFKB1APEX1 | |
| Thymotrinan SCHEMBL1738371 | 0.90 | NPY1R (0.53) | CYP1A2GLATSHRNFKB1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2025067293-A1 | HELICASE AND USE THEREOF | 北京齐碳科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119709689-A | Helicase and application thereof | 北京齐碳科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-113316641-B | Tandem protein expression | 诺维信公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2025002590-A1 | TISSUE MHC CLASS I IMMUNOPEPTIDE PATTERN DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST NON-SMALL CELL LUNG CANCER (NSCLC), IDENTIFICATION AND ISOLATION OF NSCLC SPECIFIC T CELLS IN HUMANS | UNIWERSYTET GDÁNSKI (PL) | 2025-01-02 | — | — | WO | claimed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | claimed |
| CN-116102635-A | Cathelicidin family polypeptide from aquatic mammal, and preparation method and application thereof | 中国药科大学 | 2023-05-12 | — | — | CN | claimed |
| WO-2023064631-A1 | ENGINEERING ANTIGEN BINDING TO, AND ORIENTATION ON, ADJUVANTS FOR ENHANCED HUMORAL RESPONSES AND IMMUNOFOCUSING | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| CN-115989237-A | Antimicrobial peptidomimetics | 斯派西斯公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115873092-A | Antibacterial polypeptide from banded snake, preparation method and application thereof | 中国药科大学 | 2023-03-31 | — | — | CN | claimed |
| EP-3898985-B1 | TANDEM PROTEIN EXPRESSION | NOVOZYMES AS (DK) | 2023-02-08 | — | — | EP | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-20220073898-A1 | Tandem Protein Expression | NOVOZYMES A/S (DK) | 2022-03-10 | — | — | US | claimed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | CYP1A2 3936/4885GLA 110/4885TSHR 540/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | CYP1A2 4878/4885GLA 2404/4885TSHR 1904/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | CYP1A2 2360/4885GLA 1310/4885TSHR 1625/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | CYP1A2 4878/4885GLA 2404/4885TSHR 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.